TEACH survey, a prospective survey on the incidence of venous thromboembolic events during chemotherapy for solid tumors

TEACH survey, a prospective survey on the incidence of venous thromboembolic events during chemotherapy for solid tumors - TEACH survey (Thrombo-Embolism And Chemotherapy)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30286

Enrollment

Registered

2006-11-10

Start date

2006-10-15

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer malign tumors

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age >= 18 years - Patients who are scheduled to receive chemotherapy of >= 3 months duration for cytologically or histologically proven: o breast cancer (metastatic) o colorectal cancer ((neo-) adjuvant or palliative chemotherapy) o gastric cancer ((neo-) adjuvant or palliative chemotherapy) o lung cancer ((neo-) adjuvant or palliative chemotherapy) o ovarian cancer ((neo-) adjuvant or palliative chemotherapy) o pancreatic cancer ((neo-) adjuvant or palliative chemotherapy) o prostate cancer (hormone-refractory) - Life expectancy of more than 3 months - Informed consent given by patient for data collection and ultrasonography

Exclusion criteria

Exclusion criteria: - No chemotherapy within 6 weeks before the start of the observation period - No major surgery including surgery for cancer within 4 weeks before the start of the observation period Note: minor surgery, e.g. implant of a port-a-cath, within these 4 weeks is allowed. - No major surgery including surgery for cancer planned during the observation period Note: Radiotherapy before or during the observation period is allowed. - Patients with a history of DVT or PE can be included if treatment and secondary prevention of the last episode was completed prior to survey entry. - No concurrent or scheduled use of thrombo-prophylaxis or any anticoagulant therapy such as parenteral anticoagulants (heparin, low molecular weight heparins or other agents such as fondaparinux, bivalirudin), oral anticoagulants (vitamin K antagonists) or thrombolytic agents

Design outcomes

Primary

Measure	Time frame
The primary endpoint is a composite of any of the following outcomes: * asymptomatic proximal deep vein thrombosis of the lower limbs * confirmed symptomatic deep vein thrombosis of the lower limbs * confirmed pulmonary embolism	—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results